RE:Pfizer invests in allogeneic CAR-T therapy companyJuly 14, 2023 - Caribou's gene-edited allogeneic CAR-T therapy resulted in a 44% complete response at 6 months in lympho-depleted conditioned lymphoma patients .
"... a familiar problem appears in this data that has led to questions in previous readouts: durability "
" “I wish CAR-T was the magic bullet that led to disease remission for every patient for all time. Unfortunately, that is not the case,” Haurwitz said. She says the 44% rate at six months is an important benchmark of durability."
https://www.fiercebiotech.com/biotech/car-ts-are-extraordinary-remarkable-rachel-haurwitz-makes-case-caribous-prospect-can-do-it